Michael Ehrenstein, MD

Michael Ehrenstein, MD
 

Professor of Rheumatology
University College Hospital
University College of London School of Medicine
London, UK

When are you inclined to use combination therapy with a DMARD and biologic, and when is monotherapy with a DMARD alone a reasonable strategy? Video

When are you inclined to use combination therapy with a DMARD and biologic, and when is monotherapy with a DMARD alone a reasonable strategy?

When are you inclined to use combination therapy with a DMARD and biologic, and when is monotherapy with a DMARD alone a reasonable strategy?
Michael Ehrenstein, MD

Michael Ehrenstein, MD

Why has IL-6 emerged as an important target for treating RA and through what mechanisms does inhibition of IL-6 affect the pathogenesis of RA? Video

Why has IL-6 emerged as an important target for treating RA and through what mechanisms does inhibition of IL-6 affect the pathogenesis of RA?

Why has IL-6 emerged as an important target for treating RA and through what mechanisms does inhibition of IL-6 affect the pathogenesis of RA?
Michael Ehrenstein, MD

Michael Ehrenstein, MD

How do TNFIs and IL-6 inhibitors compare as far as their effectiveness when used as monotherapy? Video

How do TNFIs and IL-6 inhibitors compare as far as their effectiveness when used as monotherapy?

How do TNFIs and IL-6 inhibitors compare as far as their effectiveness when used as monotherapy?
Michael Ehrenstein, MD

Michael Ehrenstein, MD

How does one optimize the safety profile of IL-6 inhibitors? Video

How does one optimize the safety profile of IL-6 inhibitors?

How does one optimize the safety profile of IL-6 inhibitors?
Michael Ehrenstein, MD

Michael Ehrenstein, MD

What percentage of patients who have had an inadequate response to an initial biologic agent such as TNF seem to respond to biologics with a different MOA, such as an IL-6 inhibitor? Video

What percentage of patients who have had an inadequate response to an initial biologic agent such as TNF seem to respond to biologics with a different MOA, such as an IL-6 inhibitor?

What percentage of patients who have had an inadequate response to an initial biologic agent such as TNF seem to respond to biologics with a different MOA, such as an IL-6 inhibitor?
Michael Ehrenstein, MD

Michael Ehrenstein, MD

Are there markers in RA that suggest a more progressive or aggressive disease course or that will predict non-responsiveness? Video

Are there markers in RA that suggest a more progressive or aggressive disease course or that will predict non-responsiveness?

Are there markers in RA that suggest a more progressive or aggressive disease course or that will predict non-responsiveness?
Michael Ehrenstein, MD

Michael Ehrenstein, MD

Can we use biomarkers in any way to help align therapy in RA with a specific therapeutic agent? Video

Can we use biomarkers in any way to help align therapy in RA with a specific therapeutic agent?

Can we use biomarkers in any way to help align therapy in RA with a specific therapeutic agent?
Michael Ehrenstein, MD

Michael Ehrenstein, MD

Do you modify your dose of IL-6 inhibitor if you encounter elevations in LDL level? Video

Do you modify your dose of IL-6 inhibitor if you encounter elevations in LDL level?

Do you modify your dose of IL-6 inhibitor if you encounter elevations in LDL level?
Michael Ehrenstein, MD

Michael Ehrenstein, MD